Cytotoxicity of activated natural killer cells against pediatric solid tumors

Duck Cho1, David R Shook, Noriko Shimasaki

  • 1Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.

Abstract

Insights

Expanded natural killer (NK) cells show potent cytotoxicity against pediatric Ewing sarcoma (EWS) and rhabdomyosarcoma. This NK cell expansion method is scalable and supports a phase I clinical trial for these solid tumors.

Area of Science:

  • Immunology
  • Pediatric Oncology
  • Cancer Therapy

Background:

  • Natural killer (NK) cells are crucial for innate immunity and cancer surveillance.
  • Developing novel immunotherapies for pediatric solid tumors remains a significant challenge.
  • NK cell-based therapies offer a promising avenue for treating difficult-to-treat pediatric cancers.

Purpose of the Study:

  • To evaluate the efficacy of expanded NK cells against pediatric solid tumors.
  • To identify pediatric tumor subtypes most sensitive to NK cell cytotoxicity.
  • To elucidate molecular mechanisms governing NK cell-mediated tumor killing and assess in vivo therapeutic potential.

Main Methods:

  • NK cells were expanded using K562-mb15-41BBL coculture.
  • In vitro cytotoxicity assays were performed against Ewing sarcoma (EWS), rhabdomyosarcoma, neuroblastoma, and osteosarcoma cell lines.
  • NK cell-ligand interactions, effects of chemotherapeutics, and in vivo efficacy in xenograft models were assessed.

Main Results:

  • Expanded NK cells demonstrated remarkable in vitro cytotoxicity against EWS (87.2%) and rhabdomyosarcoma (79.1%) cell lines.
  • Cytotoxicity was not correlated with NK receptor ligand expression or affected by common chemotherapeutics (daunorubicin, vincristine).
  • NK cell-mediated killing was dependent on NKGD2 and DNAM-1 receptor activation and eradicated EWS xenografts in vivo.

Conclusions:

  • Ewing sarcoma and rhabdomyosarcoma are highly sensitive to expanded NK cells among pediatric solid tumors.
  • The described NK cell expansion method is amenable to large-scale production.
  • This approach supports an ongoing phase I clinical study for patients with these malignancies.